|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1orf198 |
Gene summary for C1ORF198 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1orf198 | Gene ID | 84886 |
| Gene name | chromosome 1 open reading frame 198 | |
| Gene Alias | C1orf198 | |
| Cytomap | 1q42.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H425 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84886 | C1orf198 | LZE4T | Human | Esophagus | ESCC | 7.81e-04 | 1.52e-01 | 0.0811 |
| 84886 | C1orf198 | LZE7T | Human | Esophagus | ESCC | 3.51e-04 | 2.25e-01 | 0.0667 |
| 84886 | C1orf198 | LZE24T | Human | Esophagus | ESCC | 1.82e-09 | 3.69e-01 | 0.0596 |
| 84886 | C1orf198 | P1T-E | Human | Esophagus | ESCC | 8.72e-04 | 1.68e-01 | 0.0875 |
| 84886 | C1orf198 | P2T-E | Human | Esophagus | ESCC | 1.77e-16 | 2.27e-01 | 0.1177 |
| 84886 | C1orf198 | P4T-E | Human | Esophagus | ESCC | 1.64e-15 | 3.05e-01 | 0.1323 |
| 84886 | C1orf198 | P5T-E | Human | Esophagus | ESCC | 2.08e-17 | 3.78e-01 | 0.1327 |
| 84886 | C1orf198 | P8T-E | Human | Esophagus | ESCC | 3.37e-13 | 1.64e-01 | 0.0889 |
| 84886 | C1orf198 | P9T-E | Human | Esophagus | ESCC | 2.49e-07 | 1.81e-01 | 0.1131 |
| 84886 | C1orf198 | P10T-E | Human | Esophagus | ESCC | 9.31e-18 | 3.42e-01 | 0.116 |
| 84886 | C1orf198 | P11T-E | Human | Esophagus | ESCC | 1.92e-20 | 8.29e-01 | 0.1426 |
| 84886 | C1orf198 | P12T-E | Human | Esophagus | ESCC | 2.65e-16 | 3.73e-01 | 0.1122 |
| 84886 | C1orf198 | P15T-E | Human | Esophagus | ESCC | 1.11e-18 | 3.62e-01 | 0.1149 |
| 84886 | C1orf198 | P16T-E | Human | Esophagus | ESCC | 1.53e-12 | 2.56e-01 | 0.1153 |
| 84886 | C1orf198 | P17T-E | Human | Esophagus | ESCC | 2.26e-03 | 2.77e-01 | 0.1278 |
| 84886 | C1orf198 | P19T-E | Human | Esophagus | ESCC | 9.77e-14 | 1.25e+00 | 0.1662 |
| 84886 | C1orf198 | P20T-E | Human | Esophagus | ESCC | 6.14e-03 | 9.87e-02 | 0.1124 |
| 84886 | C1orf198 | P21T-E | Human | Esophagus | ESCC | 6.01e-08 | 2.42e-01 | 0.1617 |
| 84886 | C1orf198 | P22T-E | Human | Esophagus | ESCC | 1.06e-05 | 9.22e-02 | 0.1236 |
| 84886 | C1orf198 | P23T-E | Human | Esophagus | ESCC | 3.73e-18 | 3.76e-01 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1orf198 | SNV | Missense_Mutation | novel | c.250N>C | p.Asp84His | p.D84H | Q9H425 | protein_coding | tolerated(0.43) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| C1orf198 | SNV | Missense_Mutation | novel | c.792A>C | p.Arg264Ser | p.R264S | Q9H425 | protein_coding | tolerated(0.09) | benign(0.085) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| C1orf198 | SNV | Missense_Mutation | rs749135657 | c.596G>A | p.Arg199Gln | p.R199Q | Q9H425 | protein_coding | deleterious(0.01) | possibly_damaging(0.897) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| C1orf198 | SNV | Missense_Mutation | rs749135657 | c.596N>A | p.Arg199Gln | p.R199Q | Q9H425 | protein_coding | deleterious(0.01) | possibly_damaging(0.897) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C1orf198 | SNV | Missense_Mutation | novel | c.742N>A | p.Leu248Ile | p.L248I | Q9H425 | protein_coding | tolerated(0.24) | benign(0.024) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C1orf198 | SNV | Missense_Mutation | rs375540477 | c.532N>A | p.Ala178Thr | p.A178T | Q9H425 | protein_coding | tolerated(0.11) | benign(0.246) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C1orf198 | SNV | Missense_Mutation | novel | c.358N>C | p.Ser120Pro | p.S120P | Q9H425 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C1orf198 | SNV | Missense_Mutation | rs370439547 | c.862N>T | p.Pro288Ser | p.P288S | Q9H425 | protein_coding | tolerated(0.77) | benign(0.005) | TCGA-AP-A1DO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C1orf198 | SNV | Missense_Mutation | novel | c.901N>A | p.Leu301Met | p.L301M | Q9H425 | protein_coding | tolerated(0.16) | possibly_damaging(0.883) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C1orf198 | SNV | Missense_Mutation | novel | c.650N>T | p.Ser217Phe | p.S217F | Q9H425 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |